Brief: Tcr² Therapeutics Announces 2021 Strategic Priorities And Milestones

TCR2 Therapeutics

08/01/2021 15:54

Jan 8 (Reuters) - TCR2 Therapeutics Inc  TCRR.O :
    * TCR² THERAPEUTICS ANNOUNCES 2021 STRATEGIC PRIORITIES AND
MILESTONES
    * TCR2 THERAPEUTICS INC - INITIAL DATA FROM ONGOING TC-110
PHASE
1/2 TRIAL ANTICIPATED IN 2021
    * TCR2 THERAPEUTICS INC - IDENTIFICATION OF GAVO-CEL
RECOMMENDED
PHASE 2 DOSE AND INITIATION OF PHASE 2 STUDY EXPECTED IN 2021
    * TCR2 THERAPEUTICS INC - ADDITIONAL DATA FROM ONGOING
GAVO-CEL
PHASE 1/2 TRIAL TO BE PRESENTED IN 1H21
    * TCR2 THERAPEUTICS - EXPECTS ITS CASH, CASH EQUIVALENTS AND
INVESTMENTS WILL FUND OPERATING EXPENSES AND CAPITAL EXPENDITURE
REQUIREMENTS INTO 2023.

Source text for Eikon:  ID:nGNX3R9nry 
Further company coverage:  TCRR.O 

 ((Reuters.Briefs@thomsonreuters.com;))